Table 2 Adverse events in EPAG+tacrolimus and EPAG monotherapy group.
Adverse events | EPAG+tacrolimus N = 76 | EPAG N = 38 | P-value |
|---|---|---|---|
Dyspepsia, n (%) | |||
Grade 2 | 2 (2.6%) | 2 (5.3%) | 0.600 |
Grade 1 | 7 (9.2%) | 2 (5.3%) | 0.715 |
Skin pruritus, n (%) | |||
Grade 2 | 1 (1.3%) | 0 (0.0%) | 1.000 |
Grade 1 | 2 (2.6%) | 1 (2.6%) | 1.000 |
Arthralgia, n (%) | |||
Grade 2 | 1 (1.3%) | 0 (0.0%) | 1.000 |
Grade 1 | 2 (2.6%) | 1 (2.6%) | 1.000 |
Elevated Cr, n (%) | |||
Grade 2 | 0 (0.0%) | 0 (0.0%) | 1.000 |
Grade 1 | 3 (3.9%) | 1 (2.6%) | 1.000 |
Elevated ALT, n (%) | |||
Grade 2 | 0 (0.0%) | 2 (5.3%) | 0.109 |
Grade 1 | 0 (0.0%) | 0 (0.0%) | 1.000 |
